---
title: Diaplacental Transfer of Anti-HCMV- and Anti-VZV-immunoglobulin G (IgG) -Antibodies at Premature and Mature Newborns
nct_id: NCT02689700
overall_status: UNKNOWN
sponsor: Johann Wolfgang Goethe University Hospital
study_type: OBSERVATIONAL
primary_condition: Materno-fetal Transfer of Anti-HCMV-IgG
countries: Germany
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02689700.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02689700"
ct_last_update_post_date: 2017-03-07
last_seen_at: "2026-05-12T07:19:29.785Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Diaplacental Transfer of Anti-HCMV- and Anti-VZV-immunoglobulin G (IgG) -Antibodies at Premature and Mature Newborns

**Official Title:** Examination of Diaplacental Transfer of IgG-antibodies Against Human Cytomegalovirus (HCMV) and Varicella-Zoster-Virus (VZV) at Premature and Mature Newborns

**NCT ID:** [NCT02689700](https://clinicaltrials.gov/study/NCT02689700)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 450
- **Lead Sponsor:** Johann Wolfgang Goethe University Hospital
- **Conditions:** Materno-fetal Transfer of Anti-HCMV-IgG, Materno-fetal Transfer of Anti-VZV-IgG
- **Start Date:** 2013-07
- **Completion Date:** 2018-07
- **CT.gov Last Update:** 2017-03-07

## Brief Summary

The aim of the study is to determine the total concentration of HCMV- and VZV-specific IgG-antibodies and the total concentration of neutralizing antibodies against HCMV in neonatal bloodstream depending on gestational age at birth.

## Detailed Description

For data gathering the investigators measure the main concentration of specific HCMV-/VZV-IgG-antibodies and the concentration of neutralizing IgG-antibodies against HCMV and VZV in maternal blood and in fetal bloodstream. Then the investigators compare the data of mother and newborn. Therefore, the investigators use the following blood samples:

Mother: Venous blood sample taken at birth (+/- three days)

Newborn: Blood sample of umbilical cord (= fetal bloodstream) taken immediately after birth.

The investigators assign the data of each newborn (gestational age at birth) to the data of their respective mother for statistical evaluation. After finishing the study the investigators will destroy all residual blood.

## Eligibility

- **Minimum age:** 1 Minute
- **Maximum age:** 10 Minutes
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* HCMV and/or VZV-seropositive pregnant woman who signed written informed consent form.

Exclusion Criteria:

* Newborns of underage mothers.
* Newborns whose mother did not sign the written informed consent.
* Pregnant women with a known hereditary or acquired immune deficiency
```

## Arms

- **HCMV antibody-transfer** — Materno-fetal HCMV antibody-Transfer form 24-41 weeks of gestation
- **VZV antibody-transfer** — Materno-fetal VZV antibody-Transfer form 24-41 weeks of gestation

## Interventions

- **Blood samples** (OTHER) — Taking blood form the umbilical cord (fetal circulation) and from the vein of the corresponding mother.

## Primary Outcomes

- **To measure the concentration of specific HCMV-/VZV-IgG-antibodies in fetal bloodstream depending on gestational age at birth.** _(time frame: Newborn: immediately after birth; Mother +/- 3 days at birth)_ — Measurement of HCMV and VZV-antibodies in the fetal and the maternal circulation

## Secondary Outcomes

- **Gauging the concentration of neutralizing IgG-antibodies against HCMV and VZV in fetal bloodstream depending on gestational age at birth.** _(time frame: Newborn: immediately after birth; Mother +/- 3 days at birth)_

## Locations (1)

- Clinic of the Johann Wolfgang-Goethe Univeristy, Frankfurt am Main, Hesse, Germany — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.clinic of the johann wolfgang-goethe univeristy|frankfurt am main|hesse|germany` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02689700.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02689700*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*